UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Neurogen Corporation
- -----------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.025 par value
- -----------------------------------------------------------------------------
(Title of Class of Securities)
64124E106
- -----------------------------------------------------------------------------
(CUSIP Number)
Thomas J. Tisch
667 Madison Avenue
New York, NY 10021
(212) 545-2927
- -----------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
December 12, 1997
- -----------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
SCHEDULE 13D
CUSIP No. 64124E106 Page 2 of 5 Pages
- -----------------------------------------------------------------------------
- -------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Four Partners
- -------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
(b) |_|
- -------- --------------------------------------------------------------------
3 SEC USE ONLY
- -------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- -------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) |_|
- -------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
- -----------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 1,408,200
----------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY -0-
----------------------------------------------------------
EACH
9 SOLE DISPOSITIVE POWER
REPORTING
1,408,200
----------------------------------------------------------
PERSON
10 SHARED DISPOSITIVE POWER
WITH
-0-
- -------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,408,200
- -------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* |_|
- -------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.8%
- -------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
- -------- --------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE>
- -----------------------------------------------------------------------------
CUSIP NO. 64124E106 13D Page 3 of 5 Pages
- -----------------------------------------------------------------------------
This Amendment No. 3 amends the Schedule 13D filed by Four Partners, a
New York general partnership ("FP"), with the Securities and Exchange Commission
on April 21, 1997, as amended by Amendment No. 1 filed on June 19, 1997 and
Amendment No. 2 filed on August 7, 1997, and relates to the acquisition,
subsequent to the filing of Amendment No. 2 to the Schedule 13D, of an
additional 275,700 shares of the Common Stock, $.025 par value per share (the
"Common Stock"), of Neurogen Corporation (the "Issuer").
Item 3. Source and Amount of Funds or Other Consideration.
All funds used to purchase the securities reported in Item 5 below were
provided from the working capital of FP. The aggregate purchase price of such
securities was approximately $23,851,853.
Item 5. Interest in Securities of the Issuer.
FP holds 1,408,200 shares, representing 9.8% of the outstanding shares
of Common Stock.
(a) Set forth in the table below is the aggregate number of shares of
Common Stock beneficially owned as of the date hereof by each person or entity
listed in Item 2 above, together with the percentage of outstanding shares of
Common Stock which is beneficially owned by each such person or entity.
<PAGE>
- -----------------------------------------------------------------------------
CUSIP NO. 64124E106 13D Page 4 of 5 Pages
- -----------------------------------------------------------------------------
Name of Amount and Nature of % of Class
Beneficial Owner Beneficial Ownership Outstanding (1)
- ---------------- -------------------- -----------
Four Partners 1,408,200 9.8%
Andrew H. Tisch 0 (2) 0
1991 Trust
Daniel R. Tisch 0 (2) 0
1991 Trust
James S. Tisch 0 (2) 0
1991 Trust
Thomas J. Tisch 0 (2) 0
1991 Trust
Andrew H. Tisch 0 (2) 0
Daniel R. Tisch 0 (2) 0
James S. Tisch 0 (2) 0
Thomas J. Tisch 0 (2) 0
---------------- ----
Total 1,408,200 9.8%
(b) With respect to the persons and entities named in response to
paragraph (a) above:
(i) FP has directly the sole power to vote or direct the vote and
dispose or direct the disposition of the 1,408,200 shares of Common Stock
owned by it;
and (ii) By virtue of their status as managing trustees of the trusts
which are the general partners of FP, the Messrs. Tisch may be deemed to
have indirectly shared
- --------
(1) The Issuer's 10-Q for the fiscal quarter ended
September 30, 1997 indicated that 14,390,786 shares of
Common Stock were issued and outstanding as of
November 13, 1997.
(2) Does not include shares owned by FP. None of the Messrs.
Tisch beneficially owns any shares of Common Stock,
except to the extent that beneficial ownership of shares
of Common Stock beneficially owned by FP may be
attributed to them.
<PAGE>
- -----------------------------------------------------------------------------
CUSIP NO. 64124E106 13D Page 5 of 5 Pages
- -----------------------------------------------------------------------------
power to vote or direct the vote and dispose or direct the disposition of
the 1,408,200 shares of Common Stock owned by FP.
(c) The following transactions were effected by FP during the sixty
days preceding the date hereof or since the most recent filing on Schedule 13D,
whichever is less. None of the persons or entities named in Item 2 above
effected any other transactions in the Common Stock during the 60 days preceding
the date hereof.
Transaction Date Security No. Price/Share Market
- ----------- ---- -------- --- ----------- ------
Purchase 12/09/97 Common 50,000 $13.500 NASDAQ
Purchase 12/12/97 Common 121,000 $14.125 NASDAQ
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
hereby certify that the information set forth in this statement is true,
complete and correct.
December 15, 1997
FOUR PARTNERS
By /s/ Thomas J. Tisch
Thomas J. Tisch
Manager of Four Partners
